GlassScriptPhysician profile
Byron Michael Breeding
NPI 1548241359
$8,567.87
in general payments reported to CMS, 2019-2025
33 companies · $1,605 in 2025
The $1,605 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,894 · 2022: $1,694 · 2023: $1,533 · 2024: $1,843 · 2025: $1,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,980.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,927.27 | 2021-2025 | |
| Novo Nordisk INC | $1,339.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $766.54 | 2021-2025 | |
| Lilly USA, LLC | $645.05 | 2021-2025 | Mounjaro, Kisunla, Zepbound |
| Amgen INC. | $414.66 | 2021-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.73 | 2021-2025 | Synjardy, Jardiance, Tradjenta |
| Lundbeck LLC | $357.43 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $286.76 | 2021-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $264.09 | 2021 | |
| Janssen Pharmaceuticals, INC | $260.46 | 2021-2024 | Spravato, Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $251.92 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $204.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $190.90 | 2022-2024 | |
| Amarin Pharma, INC. | $187.03 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.35 | 2022-2025 | Caplyta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.51 | 2023-2024 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $102.83 | 2024-2025 | Voquezna |
| Acadia Pharmaceuticals INC | $101.99 | 2023-2025 | Daybue |
| Axsome Therapeutics, INC. | $91.72 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $74.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $67.53 | 2022-2023 | |
| Glaxosmithkline, LLC. | $47.14 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $43.24 | 2022-2023 | Austedo Xr |
| Antares Pharma, INC. | $40.39 | 2024 | Xyosted |
| Xeris Pharmaceuticals, INC. | $40.39 | 2024 | Gvoke Hypopen |
| Paratek Pharmaceuticals, INC. | $35.05 | 2025 | Nuzyra |
| Mylan Specialty L.P. | $33.16 | 2021 | |
| Medtronic, INC. | $27.88 | 2021-2023 | Inpen Smart Insulin Delivery System |
| Idorsia Pharmaceuticals US INC | $20.36 | 2022 | |
| Radius Health, INC. | $20.16 | 2024 | Tymlos |
| Merck Sharp & Dohme LLC | $13.92 | 2021 | |
| Sanofi Pasteur INC. | $13.54 | 2023 | |
| Eisai INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Breeding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.